The UK and US have finalized a key bilateral deal that will ensure zero duties on UK medicine exports entering the US market.
The Terms of the Deal
As part of the deal, the UK has pledged to increase expenditure on drugs through the NHS. This commitment ensures that duties on these vital goods will remain at zero for a timeframe of the next three years.
This development follows previous warnings to dramatically increase duties on branded pharmaceutical imports, with potential rates floated as high as double the cost.
"This agreement between the UK bolsters the international landscape for new treatments and introduces long-overdue balance to American-British medicine commerce," an announcement declared.
Commercial Importance
Medicines represent one of the the United Kingdom's most significant export categories to the United States, which is easily the largest buyer for large UK drugmakers.
Export figures show that in the 12 months prior to September, the UK sold medicines valued at billions to the US. This figure accounted for nearly one-fifth of total UK exports in that period.
"This guarantee protects jobs, boosts investment and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a minister commented.
Detailed British Pledges
The pact involves several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a goal to raise overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The amount drug companies must return to the NHS to control costs will be capped at 15%. Last year, rebates exceeded 20%.
Recent Tensions
The pact follows a long-running tension between the sector and the ministers over drug pricing and approval rates.
The disagreement were intensified by assertions that US patients were paying several times more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been paused or cancelled, while major investments have been directed toward American operations.
The Science Minister stated that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its total funding over the last ten years.
